The Renaissance of Interest in Breast Cancer Treatment by PD1/PDL1 Checkpoint Inhibitors
muhammad, S., Ismail, E., Abdelaziz, L., Elsebai, E. (2023). The Renaissance of Interest in Breast Cancer Treatment by PD1/PDL1 Checkpoint Inhibitors. EKB Journal Management System, 29(4), 1007-1012. doi: 10.21608/zumj.2022.100350.2374
shireen muhammad; Eman I Ismail; Lobna A. Abdelaziz; Eman Elsebai. "The Renaissance of Interest in Breast Cancer Treatment by PD1/PDL1 Checkpoint Inhibitors". EKB Journal Management System, 29, 4, 2023, 1007-1012. doi: 10.21608/zumj.2022.100350.2374
muhammad, S., Ismail, E., Abdelaziz, L., Elsebai, E. (2023). 'The Renaissance of Interest in Breast Cancer Treatment by PD1/PDL1 Checkpoint Inhibitors', EKB Journal Management System, 29(4), pp. 1007-1012. doi: 10.21608/zumj.2022.100350.2374
muhammad, S., Ismail, E., Abdelaziz, L., Elsebai, E. The Renaissance of Interest in Breast Cancer Treatment by PD1/PDL1 Checkpoint Inhibitors. EKB Journal Management System, 2023; 29(4): 1007-1012. doi: 10.21608/zumj.2022.100350.2374

The Renaissance of Interest in Breast Cancer Treatment by PD1/PDL1 Checkpoint Inhibitors

Zagazig University Medical Journal
Article 5, Volume 29, Issue 4, July and August 2023, Page 1007-1012  XML PDF (442.01 K)
Document Type: Review Articles
DOI: 10.21608/zumj.2022.100350.2374
View on SCiNiTO View on SCiNiTO
Authors
shireen muhammad email orcid 1; Eman I Ismail2; Lobna A. Abdelaziz2; Eman Elsebaiorcid 2
1Department of Clinical Oncology and Nuclear Medicine.Faculty of medicine.Zagazig University.Egypt
2Clinical oncology and nuclear medicine department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Abstract
Background:
Breast cancer is the most common cancer in females. It is the main cause of cancer-related deaths in women. Despite the benefit of using standard treatment modalities like chemotherapy, anti-Her-2 monoclonal antibodies, and hormonal therapy in the prognosis of breast cancer, 15% of breast cancer patients will have metastases and die. Grand effort has been given to understand breast cancer oncogenesis which helped with the approval of several drugs targeting cancer cells like immune therapy. The immune system has a significant role in the behavior of cancer. Contemporary, immunotherapy development through the immune checkpoint blockers demonstrated promising antitumor effects in multiple cancers that don’t respond to conventional treatments. Despite promising results, a good response is seen only in part of patients, and there is still a need for a monotherapy modality with curative ability.
Conclusion:
PD-1/L1 pathway aids the development and progression of cancer. It promotes cancer by negatively regulating the immune responses mediated by T-cells and inhibiting proliferation, migration, and effector function of T cells. PD-1/L1 blockade treatment showed a promising effect in cancer immunotherapy. This type of immunotherapy is significantly effective in malignancies containing a high expression of PDL-1/2.
Keywords
Breast cancer; PD-1 PD-L1; inhibitors; Immune response
Statistics
Article View: 185
PDF Download: 89